HLA-C and cancer: The application of stem cells in the realm of cancer vaccines started with embryonic stem cells (ESCs) [155]; considering that ESCs are usually obtained from an unrelated donor, they express a mismatched MHC and minor histocompatibility (miH) antigens (which are peptides derived from normal self-proteins that, in humans, are presented by HLA), and if transplanted in the host, they will cause alloimmune responses [156,157,158].